Although the cIMPACT-NOW 3 signature was recommended to refine the classification of IDHwt gliomas, we sought to assess whether it also occurred in cases with IDH1/2 mutations and if it impacts upon prognosis in this subgroup of gliomas. Here, IDH1 is linked to glioma.